Cleancard vs Grok
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC S23 at-home 30-minute cancer screening for prostate, bladder, and ovarian cancers; $846K Mayo Clinic/TQ Ventures/YC-backed with synthetic biology + computer vision from Oxford Rhodes Scholar founders competing with GRAIL for accessible early cancer detection.
About
Cleancard is a United States-based at-home cancer screening company — backed by Y Combinator (S23) with $846,000 in total funding from Mayo Clinic Platform, TQ Ventures, Urban Innovation Fund, Y Combinator, and the Creative Destruction Lab — developing a 30-minute at-home diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers from a single patient sample for prostate, bladder, and ovarian cancers. Founded by Luca Springer and Thomas Carroll (both Rhodes Scholars from Oxford), Cleancard targets the massive unmet need for accessible, affordable cancer screening outside of clinical settings — the 30-minute result time and home-based format enabling screening at the frequency and convenience required for early cancer detection programs.
AI assistant by xAI (Elon Musk); Grok 3 topped reasoning benchmarks in Feb 2025; 1M+ paying subscribers in week one; real-time X post access; distributed via X Premium; xAI valued at $24B.
About
Grok is the AI assistant developed by xAI, Elon Musk's AI company founded in 2023, and distributed primarily through X (formerly Twitter). Grok launched in November 2023 as an X Premium perk, with the notable differentiator of real-time access to X posts and a less restricted, more direct conversational style. Grok 3, released in February 2025, achieved top scores on the AIME math reasoning benchmark and ARC-AGI test, briefly positioning xAI as a frontier model lab.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.